Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Gilead Sciences has underperformed the broader market ... The company’s earnings surprise history is mixed. It beat the consensus estimate in three of the past four quarters while missing ...

MISSISSAUGA — Gilead Sciences Canada, Inc. (Gilead Canada ... He reportedly brings a work history across nearly every aspect ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq ... weighing at least 14 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options begin trading today, for the December 6th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

About Gilead Sciences Gilead Sciences ... are receiving chronic hemodialysis and have no antiretroviral treatment history. For patients weighing ≥14 kg to <25 kg, not recommended in patients ...

Gilead Sciences (GILD) is a leading biopharmaceutical company focused ... backed by a payout ratio of 43.40% and a 13-year history of consecutive dividend increases. Amgen reported robust financial ...